Description
SARS-CoV-2 Spike Glycoprotein Cell Line is a stable cell line for COVID-19 research. It was developed by stably transfecting HEK293T cells with a SARS-CoV-2 Spike Glycoprotein expression plasmid. These cells provide consistent levels of expression of human SARS-CoV-2 Spike Glycoprotein in cells surface. Each vial of cells contains more than 3 million viable cells stably expressing SARS-CoV-2 Spike Glycoprotein with hygromycin resistance gene.
This stable cell line is ready to use in cell-based assay applications such as the host-receptor interactions in COVID-19 research and high throughput screening for potential therapeutics for treating COVID-19. This stably transfected clonal cell line provides consistent levels of expression, which helps simplify the interpretation of results. SARS-CoV-2 Spike Glycoprotein HEK293T Cells also allow to establish in vitro models for High Throughput and High Content Screening.
Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, such as respiratory, enteric, renal, and neurological diseases. According to recent studies, the novel coronavirus SARS-CoV-2 uses its spike glycoprotein (S), a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry. It uses hACE2 to enter cells, correlating with the efficient spread of SARS-CoV-2 among humans. S comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and fusion of the viral and cellular membranes (S2 subunit). SARS-CoV-2 Spike Glycoprotein Cell Line allows the study of SARS-CoV-2 spike/ ACE2 interaction in cell-based assays. These cells stable expressing SARS-CoV-2 Spike Glycoprotein are ideal for screening antiviral drugs which target the spike proteins for COVID-19.
Cell Online also offers many other cell lines for COVID-19 research. Take a look at this page and find your needs!
Reviews
There are no reviews yet.